Published 3 months ago • loading... • Updated 3 months ago

M&G champions UK innovation in drug discovery by leading US$50 million funding round for biotech company bit.bio

On Jan. 9, 2026, M&G Investments led a US$50 million Series C for bit.bio, Cambridge-based biotech pioneering human cell programming technology.
Founded as a 2016 spin-out from the University of Cambridge, bit.bio has raised over $200 million to date to accelerate product development and enter the multi-billion toxicology market.
Bit.bio's AI-enabled discovery platform and 'opti-ox' technology program iPSCs into scalable, pure human cells, while the ioCells portfolio includes more than 50 products for pharmaceutical, biotech and academic customers.
Lord David Prior joins the board as independent director and new Board Chair to support commercial expansion, while Przemek Obloj, Chief Executive of bit.bio, said the backing expands customer reach worldwide.
The technology underpins New Approach Methodologies that reduce reliance on animal testing and improve pre-clinical relevance, positioning bit.bio as a UK success story poised for international growth.

Insights by Ground AI

30 Articles

The Courier-Tribune

+29 Reposted by 29 other sources

Center

M&G champions UK innovation in drug discovery by leading US$50 million funding round for biotech company bit.bio

LONDON, Jan. 9, 2026 /PRNewswire/ -- M&G Investments (M&G) today announces that it has led a US$50 million Series C funding round for bit.bio, the Cambridge-based biotech company pioneering next-generation human cell programming technology. The investment of patient capital into…

3 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year